In recent years, asparaginase (ASP) (or pegaspargase)-containing regimens showed prominent activity against NKTCL in a number of reports when historically compared with non-ASP-containing regimens and they are recommended by guidelines [18, 22]. The gene discussed is ASPG; the disease is extranodal nasal NK/T cell lymphoma.